Xlife Sciences AG BOERSE MUENCHEN

Equities

XLS

CH0461929603

Biotechnology & Medical Research

Market Closed - BOERSE MUENCHEN 01:43:00 2022-02-10 pm EST 5-day change 1st Jan Change
41.8 EUR -0.48% Intraday chart for Xlife Sciences AG -7.52% -3.69%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Switzerland’s Xlife Sciences, Abu Dhabi Expand Existing Life Sciences Partnership MT
Xlife Sciences, Quant Team Up to Develop Biomarkers for Kidney Diseases Detection MT
Xlife Sciences to Sell Portfolio Company to 4D Lifetec MT
Xlife Sciences AG acquired 20% stake in 4D Lifetec AG for CHF 23.3 million. CI
Xlife Sciences Loss Narrows in H1; Revenue Declines MT
Xlife Sciences AG Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Xlife Sciences AG Signs Memorandum of Understanding with the Regulator of the Healthcare Sector in the UAE, the Department of Health - Abu Dhabi CI
Xlife Sciences AG Announces Bernhard Scholz Will Not Stand for Re-Election CI
Xlife Sciences Posts Lower FY22 EPS; Revenue Increases MT
Xlife Sciences AG Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Xlife Sciences Portfolio Company Receives European Patent for Biological Tissue Generation Method MT
Xlife Sciences' Portfolio Company To Research Therapy For Amyotrophic Lateral Sclerosis MT
Xlife Sciences AG Launches Project to Research a Potential Therapy for Amyotrophic Lateral Sclerosis CI
Xlife Sciences Portfolio Company Signs Exclusive License Agreement MT
Xlife Sciences Unit Taps CureDiab For Morbid Obesity Research MT
Xlife Sciences Begins Strategic Options Review To Accelerate Business Expansion MT
Xlife Sciences' Portfolio Company Wins US Patent for Active Ingredient of Inflammatory Pain Drug MT
Xlife Sciences AG Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Xlife Sciences' H1 Loss Widen, Revenue Jumps in First Report Since SIX Swiss Transfer MT
Xlife Sciences Adopts Annual ESG Reporting To Boost Transparency MT
Xlife Sciences AG Announces Management Changes CI
Xlife Sciences AG(SWX:XLS) added to Swiss Performance Index (Price Return) CI
Xlife Sciences AG announced that it has received CHF 5.012469 million in funding CI
Curasan AG and Xlife Sciences AG Cooperate in the Field of Regenerative Medicine CI
Chart Xlife Sciences AG
More charts
Xlife Sciences AG is a Switzerland-based biotechnology company. The Company focuses on investing in technologies in the life science industry. It supports researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. The Company offers its investors direct access to the further development of technologies at a very early stage. The Company cooperates with industrial partners and universities.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
45 CHF
Average target price
68 CHF
Spread / Average Target
+51.11%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Xlife Sciences AG
  4. Stock Xlife Sciences AG - BOERSE MUENCHEN
  5. News Xlife Sciences AG
  6. Xlife Sciences' : Inventum Genetics Joins Forces with Marburg University